ACE2 News and Research

RSS

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Metal complexes against coronavirus

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 3.42 million deaths worldwide. Despite the fact that there are vaccines for SARS-CoV-2, the emergence of new variants and the lack of adequate treatments have encouraged the search for new ways to combat this disease more effectively.

21 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Researchers in the UK have developed a protein-based subunit vaccine directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could serve as an alternative to the mRNA-based vaccines currently approved for protecting against coronavirus disease 2019 (COVID-19).

20 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

A new report in the British Medical Journal indicates that newborns have a lower abundance of entry receptors for SARS-CoV-2.

19 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Researchers have reported the first case of COVID-19 triggering a rare occurrence of potentially severe blood clots forming in the arms.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

In a new study posted to the bioRxiv* preprint server, researchers from the United States report that two iminosugar glucosidase inhibitors have the ability to suppress the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tissue culture – at concentrations of at least 100 times lower than required for cytotoxic effects.

19 May 2021

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Researchers in the United States have provided the first evidence that messenger RNA (mRNA)-based vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2) induce a broader array of antibody subtypes against the viral spike protein than natural infection does.

19 May 2021

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

In a new study, researchers used an antibody discovery technology to identify a new potently neutralizing antibody with a unique mode of SARS-CoV-2 recognition. They reported their results on the bioRxiv preprint server.

18 May 2021

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Researchers discovered the first N440K variant and the new E484Q and L452R Indian variants isolated in France in a recent study. They presented the genetic mutations in the isolated genomes and the phylogenetic tree, including these strains among different SARS-CoV-2 clades. This work is posted on the bioRxiv preprint server.

18 May 2021

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Researchers in the United States have demonstrated the long-term durability of the antibody responses elicited by Moderna’s mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 May 2021

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

A new research paper published in the journal Science explores the differences in coronavirus-specific B memory cell repertoires in children versus adults, as well as the functional importance of this discovery.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

In a recently published research paper in the journal Nature Communications, a team of scientists from China has described the antiviral efficacy of a novel anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody isolated from recovered coronavirus disease 2019 (COVID-19) patients.

17 May 2021

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

The World Health Organization (WHO) has labeled the double mutant B.1.617 variant — first discovered in India —a variant of concern for its high transmission rate and ability to evade immune responses. New research posted to the preprint server bioRxiv finds B.1.617 can modestly reduce neutralizing antibody responses generated from the Pfizer-BioNTech vaccine.

16 May 2021

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A new study published in the Proceedings of the National Academy of Sciences shows that the vast majority of the viral load in a community at any given point is present in a very small minority of the infected population, underlining the vast differences in viral loads between individuals.

14 May 2021

A look at how coronavirus disease (COVID-19) affects Parkinson's

Earlier, herpes simplex virus (HSV), influenza virus A, measles virus, cytomegalovirus (CMV), and mumps virus have all been associated with after-effects of the virus that includes Parkinson's disease (PD). This list may now include SARS-CoV-2.

14 May 2021

ACE2 News and Research

Facets of SARS-CoV-2 infection and animal models

Metal complexes against coronavirus

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

Protein-based vaccines against SARS-CoV-2 may provide advantages over mRNA-based vaccines

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Nasal epithelium in newborn infants express fewer receptors for SARS-CoV-2 than adults

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Glucosidase inhibitors hold promise as novel therapeutic agents against SARS-CoV-2

Antibody response following SARS-CoV-2 mRNA vaccine is greater than natural infection

Potent antibody with unique genetic signature and spike recognition mechanism neutralizes SARS-CoV-2

SARS-CoV-2 B.1.1.420 and B.1.617.1 immune escape variants reported in France

Moderna's COVID-19 vaccine elicits six-month antibody responses to variants

Milder COVID-19 in children may be due to higher memory B cells responses to SARS-CoV-2

Nanotechnology and COVID-19 diagnosis and treatment

A SARS-CoV-2 neutralizing antibody with extensive spike binding coverage

SARS-CoV-2 B.1.617 variant shows modest resistance to vaccine-induced antibodies

Supercarriers: Just 2% of SARS-CoV-2 positive people carry 90% of the virus

A look at how coronavirus disease (COVID-19) affects Parkinson's

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News